DBV Technologies Refreshes $150M ATM Program for Manufacturing and Launch Prep
Event summary
- DBV Technologies filed a new Form S-3ASR with the SEC to refresh its ATM program, allowing up to $150M in ADS sales.
- Proceeds will fund manufacturing expansion, BLA preparations for Viaskin Peanut, and general corporate purposes.
- The ATM Program was originally established in September 2025 with Citizens JMP Securities as the sales agent.
- No prospectus approval is required from the AMF due to exemptions under EU regulations.
The big picture
DBV Technologies' move to refresh its ATM program underscores the capital-intensive nature of late-stage biopharmaceutical development, particularly in the competitive food allergy treatment space. The $150M offering reflects both the company's strategic focus on scaling manufacturing and preparing for potential regulatory approvals, as well as broader industry trends toward flexible funding mechanisms in biotech.
What we're watching
- Execution Risk
- How DBV Technologies will allocate the $150M to balance manufacturing expansion and clinical development timelines.
- Market Dynamics
- Whether the refreshed ATM program signals increased capital needs ahead of potential Viaskin Peanut approvals.
- Regulatory Headwinds
- The pace at which DBV can navigate U.S. and EU regulatory requirements for its food allergy treatments.
Related topics